Volume 10 Supplement 3

Symposium Mammographicum 2008

Open Access

Introduction to proton (H) magnetic resonance spectroscopy of the breast

  • L Bartella1
Breast Cancer Research200810(Suppl 3):P9

https://doi.org/10.1186/bcr2007

Published: 7 July 2008

Proton magnetic resonance spectroscopy (1H MRS) provides biochemical information about the tissue under investigation. The diagnostic value of 1H MRS in cancer is typically based on the detection of elevated levels of choline compounds, which is a marker of active tumor [1]. Breast 1H MRS is performed on a clinical magnet of 1.5 T or higher in field strength. A four or more channel breast coil is also needed, just as for imaging. The most widely used technique is the single voxel technique, which is limited to scan one lesion at a time. Magnetic resonance spectroscopic imaging provides information about the spatial distribution of metabolites and is useful for studying multiple lesions [2, 3]. The two main potential clinical applications of 1H MRS include its use as an adjunct to breast MRI to improve the specificity in differentiating benign from malignant lesions and in monitoring or even predicting response to treatment in patients undergoing neoadjuvant chemotherapy. Studies have suggested that 1H MRS may decrease the number of benign biopsies recommended by MRI [4, 5]. Also, in patients undergoing neoadjuvant chemotherapy, 1H MRS may be able to predict response as early as 24 hours after the first dose [6]. Currently, several limitations exist that make the technique premature for clinical use [7]. Preliminary data are promising, warranting further evaluation with larger, preferably multicenter, trials.

Authors’ Affiliations

(1)
Eastside Diagnostic Imaging

References

  1. Negendank W: Studies of human tumors by MRS: a review. NMR Biomed. 1992, 5: 303-324.View ArticlePubMedGoogle Scholar
  2. Hu J, Vartanian SA, Xuan Y, Latif Z, Soulen RL: An improved 1H magnetic resonance spectroscopic imaging technique for the human breast: preliminary results. Magn Reson Imaging. 2005, 23: 571-576. 10.1016/j.mri.2005.02.011.View ArticlePubMedGoogle Scholar
  3. Jacobs MA, Barker PB, Bottomley PA, Bhujwalla Z, Bluemke DA: Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging. 2004, 19: 68-75. 10.1002/jmri.10427.View ArticlePubMedGoogle Scholar
  4. Bartella L, Morris EA, Dershaw DD, et al: Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology. 2006, 239: 686-692. 10.1148/radiol.2393051046.View ArticlePubMedGoogle Scholar
  5. Bartella L, Thakur SB, Morris EA, et al: Enhancing non mass lesions in the breast: evaluation with proton (1H) MR spectroscopy. Radiology. 2007, 245: 80-87. 10.1148/radiol.2451061639.View ArticlePubMedGoogle Scholar
  6. Meisamy S, Bolan PJ, Baker EH, et al: Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo 1H MR spectroscopy: a pilot study at 4T. Radiology. 2004, 233: 424-431. 10.1148/radiol.2332031285.View ArticlePubMedGoogle Scholar
  7. Bartella L, Huang W: Proton MR spectroscopy (1H MRS) of the breast. Radiographics. 2007, 27: S241-S252. 10.1148/rg.27si075504.View ArticlePubMedGoogle Scholar

Copyright

© BioMed Central Ltd 2008

Advertisement